niraparib
Also known as compound 56 [PMID 19873981], MK 4827, MK-4827, Zejula
Niraparib, sold under the brand name Zejula, is an anti-cancer medication used for the treatment of epithelial ovarian, fallopian tube, or primary peritoneal cancer. It is taken by mouth. It is a PARP inhibitor.
Key facts
- Drug.legal_AU
- S4
- Drug.image
- Niraparib.svg
- Drug.image_class
- skin-invert-image
- Drug.caption
- Above: molecular structure of niraparib Below: 3D representation of a niraparib molecule
- Drug.image2
- Niraparib 3D.png
- Drug.image_class2
- bg-transparent
- Drug.tradename
- Zejula
- Drug.MedlinePlus
- a617007
- Drug.DailyMedID
- Niraparib
- Drug.pregnancy_AU
- D
- Drug.routes_of_administration
- By mouth
- Drug.ATC_prefix
- L01
- Drug.ATC_suffix
Article
12 sectionsContents
- Medical uses
- Contraindications
- Side effects
- Interactions
- Pharmacology
- Mechanism of action
- Pharmacokinetics
- Chemistry
- Studies
- History
- References
- External links
Niraparib, sold under the brand name Zejula, is an anti-cancer medication used for the treatment of epithelial ovarian, fallopian tube, or primary peritoneal cancer. It is taken by mouth. It is a PARP inhibitor.
The most common side effects include nausea (feeling sick), thrombocytopenia (low blood platelet counts), tiredness and weakness, anemia (low red blood cell counts), constipation, vomiting, abdominal (belly) pain, neutropenia (low levels of neutrophils, a type of white blood cell), insomnia (difficulty sleeping), headache, lack of appetite, diarrhea, dyspnea (difficulty breathing), hypertension (high blood pressure), back pain, dizziness, cough, joint pain, hot flushes and decrease in white blood cells.